TrialSignal
Clinical trial intelligence report
Efficacy and Safety of Cossac L Tablet in Vasomotor Rhinitis Patients : A Randomized, Double-blind, Placebo-controlled, Phase 3 Clinical Trial
Source-linked diligence brief with registry provenance, taxonomy normalization and premium analytical context.
Generated
Jun 20, 2026
NCT ID
NCT01509209
Status
COMPLETED
Phase
PHASE3
Sponsor
Hanmi Pharmaceutical Company Limited
Executive brief
Investment-Ready Snapshot
The purpose of this study is to evaluate efficacy and safety of Cossac L tablet in the treatment of vasomotor rhinitis
Source & freshness
Provenance
https://clinicaltrials.gov/study/NCT01509209
Indication
Vasomotor Rhinitis
Modality
small molecule
Target
Pseudoephedrine / Levocetirizine
Intervention
Pseudoephedrine / Levocetirizine
Source record
Protocol Description
Detailed source ingestion pending.
Source record
Outcome Measures
Detailed source ingestion pending.
Source record
Eligibility
Detailed source ingestion pending.
AI analysis
Known Results And Readout Context
Detailed source ingestion pending.
IP intelligence
Patent And IP Landscape
Detailed source ingestion pending.
Source record
Contacts
Detailed source ingestion pending.